| Name | Title | Contact Details |
|---|
Gradalis, Inc. is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of drugs, vaccines, tools, and diagnostics primarily in the area of cancer. Gradalis has its own GMP manufacturing facility along with highly skilled technical leadership and staff and a strategic partnership with Mary Crowley Cancer Research Centers for clinical development of Gradalis products. The Company has two primary platforms, one centered on personalized autologous vaccines and a second focused on bifunctional short hairpin RNA (shRNA) to enable specific protein knockdown. In addition. Gradalis has numerous partnerships and joint ventures that provide it with access to other cutting edge clinical and pre-clinical stage programs.
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry`s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma`s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson`s Imbruvica, Astellas` and Pfizer`s Xtandi, Biogen`s Tysabri, Johnson & Johnson`s Tremfya, Gilead`s Trodelvy, Merck`s Januvia, Novartis` Promacta, Vertex`s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
At Enveda, we are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. Our platform harnesses nature`s complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics.
Socati is the most advanced producer of THC-free full spectrum hemp. Purpose built for CBD infused products at global manufacturing scale, we combine expertise in seed genetics, proprietary extraction techniques and the most efficient purification systems available today. By integrating the entire supply chain, Socati is your partner in delivering to one of the most lucrative new product categories in history - non-psychoactive cannabinoid infusion.
Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company`s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara`s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California.